Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Invivyd, Inc. IVVD NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
60/100
4/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$9.50
+490.1%

Invivyd, Inc. (IVVD) is a Biotechnology company in the Healthcare sector, currently trading at $1.61. It has a SharesGrow Score of 60/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Analyst consensus target is IVVD = $10 (+490.1% upside).

Valuation: IVVD trades at a trailing Price-to-Earnings (P/E) of -5.1 (S&P 500 average ~25).

Financials: revenue is $53M, +110.5%/yr average growth. Net income is $52M (loss), growing at +33%/yr. Net profit margin is -98.2% (negative). Gross margin is 93% (-0.6 pp trend).

Balance sheet: total debt is $2M against $242M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 7.24 (strong liquidity). Debt-to-assets is 0.9%. Total assets: $277M.

Analyst outlook: 4 / 7 analysts rate IVVD as buy (57%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future 64/100 (Pass), Income 10/100 (Fail).

$9.50
▲ 490.06% Upside
Average Price Target
Based on 7 Wall Street analysts offering 12-month price targets for Invivyd, Inc., the average price target is $9.50, with a high forecast of $10.00, and a low forecast of $9.00.
Highest Price Target
$10.00
Average Price Target
$9.50
Lowest Price Target
$9.00

IVVD SharesGrow Score Overview

70/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — IVVD

✓
VALUE Pass
100/100
IVVD trades at a trailing Price-to-Earnings (P/E) of -5.1 (S&P 500 average ~25). Forward PEG -0.44 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $10, implying +521.1% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
IVVD: +110.5%/yr revenue is, +33%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet IVVD: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 7.24 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
IVVD: Gross margin is 93% (-0.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 4 / 7 analysts rate IVVD as buy (57%). Analyst consensus target is $10 (+521.1% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
IVVD: Net profit margin is -98.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.46-3.07
Volume2.48M
Avg Volume (30D)3.19M
Market Cap$213.69M
Beta (1Y)0.74
Share Statistics
EPS (TTM)-0.30
Shares Outstanding$172.21M
IPO Date2021-08-06
Employees99
CEOWilliam E. Duke Jr.
Financial Highlights & Ratios
Revenue (TTM)$53.43M
Gross Profit$49.68M
EBITDA$-53.45M
Net Income$-52.49M
Operating Income$-55.56M
Total Cash$226.69M
Total Debt$2.49M
Net Debt$-224.2M
Total Assets$276.88M
Price / Earnings (P/E)-5.4
Price / Sales (P/S)4
Analyst Forecast
1Y Price Target$9.50
Target High$10.00
Target Low$9.00
Upside+490.1%
Rating ConsensusBuy
Analysts Covering7
Buy 57% Hold 43% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS00534A1025

Price Chart

Track all markets on TradingView
IVVD
Invivyd, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
0.46 52WK RANGE 3.07

People Also View

ERAS
ERAS
Erasca, Inc.
$17.85
+9.44%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 RXRX
RXRX
Recursion Pharmaceuticals, Inc.
$3.54
+3.51%
 ICVX
ICVX
Icosavax, Inc.
$15.31
-0.91%
 EXAI
EXAI
Exscientia plc
$4.84
+0.00%
 RGNX
RGNX
REGENXBIO Inc.
$9.30
+2.88%
 AVIR
AVIR
Atea Pharmaceuticals, Inc.
$5.80
+1.58%
 ABEO
ABEO
Abeona Therapeutics Inc.
$5.19
+2.57%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message